Global infectious disease test device market to reach USD 26.8 billion by 2027..

Global infectious disease test device market Size study with COVID impact, by Product & Service (Assays, Kits, & Reagents, Instruments, Services and Software) by Disease Type (Hepatitis, HIV, CT/NG, HAIs, HPV, TB, Influenza, Other Diseases) by Technology (Immunodiagnostics, Clinical, Microbiology, PCR, INAAT, DNA Sequencing & NGS, DNA Microarrays, Other Technologies) by End User (Hospitals/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes, Other End Users) and Regional Forecasts 2020-2027
Product Code:  HALMDAE_67609862
Chapter 1.	Executive Summary 
1.1.	Market Snapshot
1.2.	Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1.	Infectious disease test device Market, by Region, 2018-2027 (USD Billion)
1.2.2.	Infectious disease test device Market, by Product and Service, 2018-2027 (USD Billion)
1.2.3.	Infectious disease test device Market, by Disease Type, 2018-2027 (USD Billion)
1.2.4.	Infectious disease test device Market, by Technology, 2018-2027 (USD Billion)
1.2.5.	Infectious disease test device Market, by End User, 2018-2027 (USD Billion)
1.3.	Key Trends
1.4.	Estimation Methodology
1.5.	Research Assumption
Chapter 2.	Global Infectious disease test device Market Definition and Scope 
2.1.	Objective of the Study
2.2.	Market Definition & Scope
2.2.1.	Scope of the Study
2.2.2.	Industry Evolution
2.3.	Years Considered for the Study
2.4.	Currency Conversion Rates
Chapter 3.	Global Infectious disease test device Market Dynamics	
3.1.	Infectious disease test device Market Impact Analysis (2018-2027)
3.1.1.	Market Drivers
3.1.2.	Market Challenges
3.1.3.	Market Opportunities
Chapter 4.	Global Infectious disease test device Market: Industry Analysis
4.1.	Porter’s 5 Force Model
4.1.1.	Bargaining Power of Suppliers
4.1.2.	Bargaining Power of Buyers
4.1.3.	Threat of New Entrants
4.1.4.	Threat of Substitutes
4.1.5.	Competitive Rivalry
4.1.6.	Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2.	PEST Analysis
4.2.1.	Political 
4.2.2.	Economical
4.2.3.	Social 
4.2.4.	Technological 
4.3.	Investment Adoption Model
4.4.	Analyst Recommendation & Conclusion
Chapter 5.	Global Infectious disease test device Market, by Product and Service 
5.1.	Market Snapshot 
5.2.	Global Infectious disease test device Market by Product and Service, Performance - Potential Analysis
5.3.	Global Infectious disease test device Market Estimates & Forecasts by Product and Service 2017-2027 (USD Billion)
5.4.	Infectious disease test device Market, Sub Segment Analysis
5.4.1.	 Assays, Kits, & Reagents
5.4.2.	Instruments
5.4.3.	Services and Software
Chapter 6.	Global Infectious disease test device Market, by Disease Type         
6.1.	Market Snapshot 
6.2.	Global Infectious disease test device Market by Disease Type, Performance - Potential Analysis
6.3.	Global Infectious disease test device Market Estimates & Forecasts by Disease Type2017-2027 (USD Billion)
6.4.	Infectious disease test device Market, Sub Segment Analysis
6.4.1.	 Hepatitis
6.4.2.	HIV
6.4.3.	CT/NG
6.4.4.	HAIs
6.4.5.	HPV
6.4.6.	TB
6.4.7.	Influenza 
Chapter 7.	Global Infectious disease test device Market, by Technology         
7.1.	Market Snapshot 
7.2.	Global Infectious disease test device Market by Technology, Performance - Potential Analysis
7.3.	Global Infectious disease test device Market Estimates & Forecasts by Technology 2017-2027 (USD Billion)
7.4.	Infectious disease test device Market, Sub Segment Analysis
7.4.1.	Immunodiagnostics
7.4.2.	Clinical Microbiology
7.4.3.	PCR
7.4.4.	INAAT
7.4.5.	DNA Sequencing & NGS
7.4.6.	DNA Microarrays 
Chapter 8.	Global Infectious disease test device Market, by End User         
8.1.	Market Snapshot 
8.2.	Global Infectious disease test device Market by End User, Performance - Potential Analysis
8.3.	Global Infectious disease test device Market Estimates & Forecasts by End User 2017-2027 (USD Billion)
8.4.	Infectious disease test device Market, Sub Segment Analysis
8.4.1.	Hospitals/Clinical Laboratories
8.4.2.	Reference Laboratories
8.4.3.	Physician Offices
8.4.4.	Academic/Research Institutes


Chapter 9.	Global Infectious disease test device Market, Regional Analysis
9.1.	Infectious disease test device Market, Regional Market Snapshot 
9.2.	North America Infectious disease test device Market 
9.2.1.	U.S. Infectious disease test device Market
9.2.1.1.	 Product and Service breakdown estimates & forecasts, 2017-2027 
9.2.1.2.	 Disease Type breakdown estimates & forecasts, 2017-2027 
9.2.1.3.	Technology breakdown estimates & forecasts, 2017-2027
9.2.1.4.	End User breakdown estimates & forecasts, 2017-2027
9.2.2.	Canada Infectious disease test device Market
9.3.	Europe Infectious disease test device Market Snapshot
9.3.1.	U.K. Infectious disease test device Market 
9.3.2.	Germany Infectious disease test device Market
9.3.3.	France Infectious disease test device Market
9.3.4.	Spain Infectious disease test device Market
9.3.5.	Italy Infectious disease test device Market
9.3.6.	Rest of Europe Infectious disease test device Market
9.4.	Asia-Pacific Infectious disease test device Market Snapshot
9.4.1.	China Infectious disease test device Market 
9.4.2.	India Infectious disease test device Market 
9.4.3.	Japan Infectious disease test device Market
9.4.4.	Australia Infectious disease test device Market
9.4.5.	South Korea Infectious disease test device Market
9.4.6.	Rest of Asia Pacific Infectious disease test device Market
9.5.	Latin America Infectious disease test device Market Snapshot
9.5.1.	Brazil Infectious disease test device Market
9.5.2.	Mexico Infectious disease test device Market
9.6.	Rest of The World Infectious disease test device Market

Chapter 10.	Competitive Intelligence
10.1.	Top Market Strategies
10.2.	Company Profiles
10.2.1.	 Metalfrio Solutions S.A.
10.2.1.1.	Key Information
10.2.1.2.	Overview
10.2.1.3.	Financial (Subject to Data Availability)
10.2.1.4.	Product Summary
10.2.1.5.	Recent Developments
10.2.2.	  Abbott Laboratories
10.2.3.	     Becton, Dickinson and Company
10.2.4.	     Biomérieux SA
10.2.5.	     Bio-Rad Laboratories
10.2.6.	     Danaher Corporation
10.2.7.	     Diasorin
10.2.8.	     Luminex
10.2.9.	     Meridian Bioscience
10.2.10.	 Quidel
10.2.11.	     Roche Diagnostics
10.2.12.	     Siemens AG
10.2.13.	     Thermo Fisher Scientific 
Chapter 11.	Research Process
11.1.	Research Process
11.1.1.	Data Mining
11.1.2.	Analysis
11.1.3.	Market Estimation
11.1.4.	Validation
11.1.5.	Publishing
11.2.	Research Attributes
11.3.	Research Assumption

Global infectious disease test device market is valued approximately at USD 16.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 5.60% over the forecast period 2020-2027. Diagnosis of infectious disease involves identifying the presence of a foreign antigen / organism using diagnostic tools like kits. Most of the currently available standard diagnostic test kits are for bacterial infections and sexually transmitted diseases.Malaria, Dengue, Leptospirosis and others diagnostic tests should, however, be replaced by molecular techniques in the future. In spite of significant improvements in sanitation practices and medicine, the global prevalence of infectious diseases such as influenza, HPV, hepatitis, HIV and tuberculosis is considerably high, which drives the market. According to NCBI, “Worldwide, 17 million HIV-infected people are receiving these life-extending drugs—an impressive number given that only 2.2 million people were on ART in 2005.” Medicare has revised its mechanism for reimbursement of some IVD tests, including molecular infectious disease tests. Some of these molecular pathology tests do not have their own HCPCS (Healthcare Common Procedure Coding System) codes, but are charged using unlisted codes, which is the restraining factor. Reimbursement for In Vitro Diagnostic (IVD) Tests examines the U.S. reimbursement system for IVD testing, which focuses on key issues of industry concern. It covers only commercialized tests, excluding those used primarily for research or developmental purposes One of the key factors leading to increased use of molecular diagnostics and genomics & proteomics technologies in infectious disease testing is growing patient awareness of the benefits of personalized medicine. Genome Canada, a funding source for genomics and proteomics, has announced plans to invest $16 million between the April 2015 to March 2017 period.

The regional analysis of global infectious disease test device market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World North America accounted for a share of just over 44.0 percent of the global market in 2019, and it is expected that this trend will continue through the forecast period. This is due to high levels of awareness among practitioners and patients, proactive government initiatives and the presence of sophisticated health care infrastructure. Asia Pacific is expected to register the highest CAGR, driven by favorable government initiatives for infectious disease testing, high unmet medical needs, economic development and consequent rise in disposable income, and increased healthcare spending in emerging countries such as China, India , and South Korea.

Major market player included in this report are:

Abbott Laboratories
Becton, Dickinson and Company
Biomérieux SA
Bio-Rad Laboratories
Danaher Corporation
Diasorin
Luminex
Meridian Bioscience
Quidel
Roche Diagnostics
Siemens AG
Thermo Fisher Scientific

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
by Product & Service
Assays, Kits, & Reagents
Instruments
Services and Software
by Disease Type
Hepatitis
HIV
CT/NG
HAIs
HPV
TB
Influenza
Other Diseases
by Technology
Immunodiagnostics
Clinical Microbiology
PCR
INAAT
DNA Sequencing & NGS
DNA Microarrays
Other Technologies
by End User
Hospitals/Clinical Laboratories
Reference Laboratories
Physician Offices
Academic/Research Institutes
Other End Users
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Urgent Care Center Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.



Loading…